CLS

Jill Kale Appointed to Celestica’s Board of Directors

Retrieved on: 
Thursday, December 1, 2022

TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing and supply chain solutions for the worlds most innovative companies, is pleased to announce the appointment of Jill Kale to its Board of Directors effective December 1, 2022.

Key Points: 
  • TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX: CLS) (NYSE: CLS), a leader in design, manufacturing and supply chain solutions for the worlds most innovative companies, is pleased to announce the appointment of Jill Kale to its Board of Directors effective December 1, 2022.
  • Id like to welcome Jill to Celesticas Board of Directors, said Mike Wilson, Chair, Celesticas Board of Directors.
  • "As a highly respected and seasoned executive with extensive experience in the aerospace and defense market, Jill will be a valued member of the Board as we continue to drive the performance of the business.
  • She currently sits on the Board of Directors of iDirect Government, LLC, a wholly owned subsidiary of ST Engineering iDirect, Inc., which provides secure satellite-based voice, video and data applications, and the Board of Directors of Hensoldt, Inc., the U.S. affiliate of Hensoldt AG, a German defense company.

Byepix Builds Metaverse Ecosystem with New Features

Retrieved on: 
Wednesday, November 23, 2022

The recent token listing has helped Byepix expand its business and brings more attention to itself.

Key Points: 
  • The recent token listing has helped Byepix expand its business and brings more attention to itself.
  • On December 19, there will be a Byepix Metaverse Voice update.
  • Following this update, people will be able to communicate on the Byepix metaverse by speaking with one another.
  • Byepix will be hosting a Web3 event in the Byepix Metaverse very soon.

OFS is Selected by DC BLOX For its Myrtle Beach to Atlanta Network

Retrieved on: 
Monday, November 14, 2022

ATLANTA, Nov. 14, 2022 /PRNewswire/ -- OFS, a leading manufacturer of innovative fiber optic products, announces it has been selected by DC BLOX, a provider of multi-tenant data centers, dark fiber, and connectivity solutions that delivers the infrastructure essential to power today's digital business. As the exclusive fiber optic cable provider, OFS is providing its industry-leading fiber optic cable for DC BLOX's Myrtle Beach, South Carolina Cable Landing Station (CLS) terrestrial network extension, connecting from the Myrtle Beach CLS, through Charleston, Augusta, and Atlanta landing in Lithia Springs, Georgia with eight strategically located network aggregation facilities enabling regional cloud computing, wireless services, local content distribution and broadband access to underserved areas in both South Carolina and Georgia.

Key Points: 
  • Debra Freitas, Chief Commercial Officer, DC BLOX Fiber comments, "we knew what we wanted to accomplish with this new network route, and OFS' large capacity fiber optic cable, leveraging the latest technology, has allowed us to increase the quality of our network while managing costs".
  • "Working with Debra and the team at DC BLOX has been a rewarding experience," says Holly Hulse, President, and CEO of OFS.
  • DC BLOX's private network fabric and robust connectivity ecosystem enable access to built-in carriers, Internet exchanges, public cloud providers, and DC BLOX data centers to businesses across the Southeast.
  • DC BLOX's data centers are located in Atlanta, GA; Birmingham, AL; Huntsville, AL; Chattanooga, TN; Greenville, SC, and a future cable landing station in Myrtle Beach, SC.

XSOLIS to Speak at the 2022 Leadership and Physician Advisor Conference in New Orleans

Retrieved on: 
Monday, November 14, 2022

NASHVILLE, Tenn., Nov. 14, 2022 /PRNewswire/ -- XSOLIS, the artificial intelligence (AI) technology company creating a more efficient healthcare system, announced today that Chief Medical Officer Heather Bassett, M.D. will speak at the 2022 Leadership and Physician Advisor Conference (LPAC), November 16-18, 2022, in New Orleans, Louisiana. Dr. Bassett will be joined by Dr. Ariana Peters, medical director, care management physician advisor at Mayo Clinic, to explore the impact of artificial intelligence in healthcare delivery and operations and how AI can be harnessed to streamline workflows and improve communication with payers.

Key Points: 
  • will speak at the 2022 Leadership and Physician Advisor Conference (LPAC), November 16-18, 2022, in New Orleans, Louisiana.
  • As a platinum sponsor, XSOLIS is hosting a number of activities throughout the three-day event.
  • Additionally, XSOLIS is hosting a happy hour from 5:30-7:30 p.m. CST on Thursday, November 17,at the Hyatt Regency Club.
  • To learn about additional opportunities to connect with XSOLIS at the 2022 Leadership and Physician Advisor Conference, visit https://www.xsolis.com/lpac-2022 .

New XL750 Transalp and EM1 e: electric vehicle lead Honda's full 23YM line-up reveal at EICMA

Retrieved on: 
Tuesday, November 8, 2022

Headlining the unveiling is the return to the Honda line-up of the evocative Transalp name in the shape of the XL750 Transalp.

Key Points: 
  • Headlining the unveiling is the return to the Honda line-up of the evocative Transalp name in the shape of the XL750 Transalp.
  • The new engine is housed in a lightweight steel diamond frame to offer light, nimble, confidence-inspiring handling in any situation.
  • For supple on-road performance and off-road bump absorption the Transalp is equipped with Showa 43mm SFF-CATM USD forks and rear shock operating through Pro-Link.
  • Styling for the Transalp has been led by Honda's Rome R&D centre, under the guiding principle of 'Friendly Toughness'.

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 9, 2022

ALPHARETTA, Ga., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  • Clearsides license and other revenue for the third quarter of 2022 was $0.3 million, compared to $3.1 million for the third quarter of 2021.
  • Research and development expenses for the third quarter of 2022 were $4.6 million, compared to $5.1 million for the third quarter of 2021.
  • General and administrative expenses for the third quarter of 2022 were $2.4 million, compared to $2.8 million for the third quarter of 2021.

DMALINK ® broadens invite for its global code of conduct order matching feature to select eFX market makers

Retrieved on: 
Monday, November 7, 2022

The firm cemented its belief in the global code of conduct by publishing a statement of commitment on the CLS register in October 2022.

Key Points: 
  • The firm cemented its belief in the global code of conduct by publishing a statement of commitment on the CLS register in October 2022.
  • The decision to adhere to the code has been confirmed by a trial run with select counterparties.
  • Michael Siwek, Founding Partner and Global Head of Sales at DMALINK, said: "Although currently voluntary, the code is a step in the right direction to benefit all market participants.
  • Manu Choudhary, CEO at DMALINK, adds: "We are thrilled to officially launch the global code of conduct streams across our London and New York trading hubs.

DMALINK ® broadens invite for its global code of conduct order matching feature to select eFX market makers

Retrieved on: 
Monday, November 7, 2022

The firm cemented its belief in the global code of conduct by publishing a statement of commitment on the CLS register in October 2022.

Key Points: 
  • The firm cemented its belief in the global code of conduct by publishing a statement of commitment on the CLS register in October 2022.
  • The decision to adhere to the code has been confirmed by a trial run with select counterparties.
  • Michael Siwek, Founding Partner and Global Head of Sales at DMALINK, said: "Although currently voluntary, the code is a step in the right direction to benefit all market participants.
  • Manu Choudhary, CEO at DMALINK, adds: "We are thrilled to officially launch the global code of conduct streams across our London and New York trading hubs.

California Life Sciences announces 19th annual Pantheon Award Winners

Retrieved on: 
Friday, November 4, 2022

SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- California Life Sciences (CLS), the states most impactful life sciences trade association, today announced the winners of its 19th annual Pantheon Awards.

Key Points: 
  • SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- California Life Sciences (CLS), the states most impactful life sciences trade association, today announced the winners of its 19th annual Pantheon Awards.
  • This years winners show how diverse and far-reaching Californias life sciences sector truly is, and we applaud their commitment to delivering innovative solutions for healthier lives.
  • The 2022 Pantheon Award winners are:
    SPARK at Stanford Translational Research Program Academia, Non-Profit, & Research Award
    Pantheon is a long-standing awards celebration that brings together more than 500 industry pioneers to recognize the contributions of leading life sciences innovators in the state.
  • About California Life Sciences: California Life Sciences (CLS) is the states most influential and impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline.

CLS Americas Exhibits TRANBERG Fusion-Guided Focal Laser Ablation Solution at Western Section AUA Meeting

Retrieved on: 
Tuesday, November 1, 2022

Physicians in the US and EU are using the TRANBERG system in clinical trials to treat patients with low-to-intermediate risk prostate cancer.

Key Points: 
  • Physicians in the US and EU are using the TRANBERG system in clinical trials to treat patients with low-to-intermediate risk prostate cancer.
  • Focal laser ablation has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.
  • CLS Americas is currently expanding its commercial market development for the TRANBERG focal laser ablation system and has two informational videos and available to view and download.
  • The Western Section AUA Meeting is an excellent venue to introduce our TRANBERG focal laser ablation system to innovative urologists from around the world, said Michael Magnani, president of CLS Americas.